Khandelwal – Indian Pharmaceutical Products
Khandelwal
Khandelwal Laboratories Pvt. Ltd. (KLab) is a privately owned Indian pharmaceutical company founded in 1945 and headquartered in Mumbai. It is led by managing director Sanjeev Khandelwal.
KLab's main areas in the Indian market are oncology, antibiotics, and pain and spasm management; besides finished medicines, it produces active substances and chiral intermediates. Oncology is one of its oldest businesses: KLab was the first to introduce cyclophosphamide (with Germany's Asta Medica) and bleomycin (with Japan's Nippon Kayaku) in India, and its cancer portfolio now includes more than 30 drugs.
The company has three WHO-GMP certified plants: in Thane (oncology medicines and active substances — injectable solutions and lyophilised powders, tablets and capsules), in Rudrapur (tablets) and in Dadra (injectables). According to the company, its oncology products are registered in more than 30 countries across Africa, Latin America, the CIS and South-East Asia. KLab also does contract manufacturing for other pharmaceutical companies.
Unifarm carries Khandelwal's oncology medicines: Xalipat (oxaliplatin), Bleocin (bleomycin), and Lastet 50 and Lastet 100 (etoposide).